Phase II Study Evaluating The Infusion Of Autologous Tumour-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma
This is a phase II clinical study for patients with metastatic (the cancer has spread to
other parts of the body) melanoma. Patients will receive an infusion (given by vein) of
autologous tumour infiltrating lymphocytes (TILs). TILs are a type of white blood cells that
recognizes tumour cells and enter them which causes the tumour cells to break down.
Prior to the cell infusion, patients will receive a two drugs cyclophosphamide and
fludarabine to prepare the body to receive the TILs. After cell infusion, patients will
receive low-dose interleukin-2 therapy which is an approved drug to treat melanoma. This
study will see how useful this regimen is in treating metastatic melanoma.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society